Lung Neoplasms
Oncology·MeSH: Lung Neoplasms
Prevalence
3358.2 / 100K
Incidence
1547.2 / 100K/yr
1 drug in development·1 company·12 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Taletrectinib | Nuvation Bio Inc. (NUVB) |
Frequently asked questions
How many drugs are in development for Lung Neoplasms?
BioSniper tracks 1 drug in development for Lung Neoplasms across 1 company.
How many clinical trials target Lung Neoplasms?
There are 12 clinical trials targeting Lung Neoplasms tracked by BioSniper.
What is the prevalence of Lung Neoplasms?
The estimated prevalence of Lung Neoplasms is approximately 3358.2 per 100,000 population.
Deep-dive into Lung Neoplasms
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis